Pfizer to close Hospira deal in September; U.K. cell manufacturing facility moves forward;

> Pfizer ($PFE) says it has all of the antitrust approvals it needs and will close on its $15 billion buyout of Hospira ($HSP) in early September. Release

> Merck KGaA stopped production July 31 at a facility in India where it made teaching kits, tech ware and molecular biology reagents and is in the process of shutting it down. Report

> Shire ($SHPG) has a new agreement with Sanquin Blood Supply, which has been the exclusive manufacturer of Cinryze, the rare disease drug it got in its $4.2 billion buyout of ViroPharma, which will allow it to use other contractors to increase production of the drug. Release

> Plans for a £55 million large-scale manufacturing facility to be run by England's Cell Therapy Catapult has been approved by local authorities in Hertfordshire. Report

> Chicago-based contract manufacturer Regis Technologies has completed a 36,000-square-foot potent compound suite to manufacturer potent APIs. Release

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

With a new £131 million contribution from the U.K. government, VMIC aims to both speed up and expand on its prior ambitions.

Pricing controversies shouldn't overshadow Phlow's promise to provide low-cost drugs to address COVID-19, says the CEO of partner Civica Rx.